Plasma homocysteine in subjects with familial combined hyperlipidemia

Atherosclerosis

Volumn 166, Issue 1, 2003, Pages 111-117

  Veerkamp, M J ^a   De Graaf, J ^a   Den Heijer, M ^a   Blom, H J ^a   Stalenhoef, A F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Familial combined hyperlipidemia; Homocysteine

Indexed keywords

CHOLESTEROL; HOMOCYSTEINE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; APOLIPOPROTEIN B;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; BODY MASS; CORONARY ARTERY DISEASE; EVALUATION; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTOR;

ADULT; APOLIPOPROTEINS B; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INSULIN RESISTANCE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS;

EID: 0037213802     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00312-X     Document Type: Article

References (43)

1. Brunzell J.D., Schrott H.G., Motulsky A.G., Bierman E.L. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism. 25:(3):1976;313-320.
2. Bredie S.J., Demacker P.N., Stalenhoef A.F. Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity. Eur. J. Clin. Invest. 27:(10):1997;802-811.
3. de Graaf J., Stalenhoef A.F. Defects of lipoprotein metabolism in familial combined hyperlipidaemia. Curr. Opin. Lipidol. 9:(3):1998;189-196.
4. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb. Haemost. 81:(2):1999;165-176.
5. Refsum H., Ueland P.M., Nygard O., Vollset S.E. Homocysteine and cardiovascular disease. Annu. Rev. Med. 49:1998;31-62.
6. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 338:(15):1998;1042-1050.
7. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:(13):1995;1049-1057.
8. Alfthan G., Pekkanen J., Jauhianen M., Pitkaniemi J., Karvanen M., Tuomilehto J., et al. Relation of serum homocysteine and lipoprotein (a) concentration to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:(1):1994;9-19.
9. Knekt P., Reunanen A., Alfthan G., Heliovaara M., Rissanen H., Marniemi J., et al. Hyperhomocysteinemia. A risk factor or a consequence of coronary heart disease? Arch. Int. Med. 161:2001;1589-1594.
10. Christen W.G., Ajani U.A., Glynn R.J., Hennekens C.H. Blood levels of homocysteine and increased risks of cardiovascular disease, causal or casual? Arch. Int. Med. 160:2000;422-434.
11. Ridker P.M., Manson J.E., Buring J.E., Shih J., Matias M., Hennekens C.H. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 281:(13):1999;1817-1821.
12. Whinchup P.H., Refsum H., Perry I.J. Serum total homocysteine and coronary heart disease: prospective study in middle aged men. Heart. 82:1999;448-454.
13. Assmann G., Schulte H. Results and conclusions of the prospective cardiovascular Munster (PROCAM) study. Assmann G. Lipid metabolism disorders and cardiovascular disease. 1993;19-68 MMV-Medzin-Verlag GmbH.
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:(6):1972;499-502.
15. Demacker P.N., Veerkamp M.J., Bredie S.J., Marcovina S.M., de Graaf J., Stalenhoef A.F. Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis. 153:(2):2000;483-490.
16. Lopes-Virella M.F., Virella G., Evans G., Malenkos S.B., Colwell J.A. Immunonephelometric assay of human apolipoprotein AI. Clin. Chem. 26:(8):1980;1205-1208.
17. Swinkels D.W., Hak-Lemmers H.L., Demacker P.N. Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions. J. Lipid Res. 28:(10):1987;1233-1239.
18. de Graaf J., Swinkels D.W., de Haan A.F., Demacker P.N., Stalenhoef A.F. Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families. Am. J. Hum. Genet. 51:(6):1992;1295-1310.
19. Stalenhoef A.F., de Graaf J., Wittekoek M.E., Bredie S.J., Demacker P.N., Kastelein J.J. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia. Atherosclerosis. 153:(1):2000;129-138.
20. Fiskerstrand T., Refsum H., Kvalheim G., Ueland P.M. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin. Chem. 39:(2):1993;263-271.
21. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:(7):1985;412-419.
22. Frosst P., Blom H.J., Milos R., et al. Identification of a candidate genetic risk factor for cardiovascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:(1):1995;111-113.
23. Heinecke J.W., Kawamura M., Suzuki L., Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J. Lipid Res. 34:(12):1993;2051-2061.
24. de Graaf J., Hak Lemmers H.L., Hectors M.P., Demacker P.N., Hendriks J.C., Stalenhoef A.F. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler. Thromb. 11:(2):1991;298-306.
25. Blom H.J., Kleinveld H.S., Boers G.H., Demacker P.N., Hak-Lemmers H.L., Te Poele-Pothoff M.T., et al. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur. J. Clin. Invest. 25:(3):1995;149-154.
26. den Heijer M., Blom H.J., Gerrits W.B., Rosendaal F.R., Haak H.L., Wijermans P.W., et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 345:(8954):1995;882-885.
27. Graham I.A., Leslie E.D., Refsum H.M., Robinson K., Brattstrom L.E., Ueland P.M., et al. Plasma homocysteine as a risk factor for vascular disease. JAMA. 277:(22):1997;1775-1781.
28. Nygard O., Vollset S.E., Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 274:(19):1995;1526-1533.
29. Christen W.G., Ajani U.A., Glynn R.J., Hennekens C.H. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch. Intern. Med. 160:(4):2000;422-434.
30. Sutton-Tyrrell K., Bostom A., Selhub J., Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation. 96:(6):1997;1745-1749.
31. Malinow M.R., Levenson J., Giral P., Nieto F.J., Razavian M., Segond P., et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocyst(e)ine concentration. Atherosclerosis. 114:(2):1995;175-183.
32. Araki A., Sako Y., Fukushima Y., Matsumoto M., Asada T., Kita T. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis. 79:(2-3):1989;139-146.
33. Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Forde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int. J. Epidemiol. 24:(4):1995;704-709.
34. Lim S., Seon K.M., Soo P.K., Ho L.J., Hee A.G., Ja Y.M., et al. Correlation of plasma homocysteine and mitochondrial DNA content in peripheral blood in healthy women. Atherosclerosis. 158:(2):2001;399-405.
35. Wu L.L., Wu J., Hunt S.C., James B.C., Vincent G.M., Williams R.R., et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin. Chem. 40:(4):1994;552-561.
36. Genest J.J. Jr., McNamara J.R., Upson B., Salem D.N., Ordovas J.M., Schaefer E.J., et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler. Thromb. 11:(5):1991;1129-1136.
37. Kang S.S., Wong P.W., Cook H.Y., Norusis M., Messer J.V. Protein-bound homocyst(e)ine. A possible risk factor for coronary artery disease. J. Clin. Invest. 77:(5):1986;1482-1486.
38. Dicker-Brown A., Fonseca V.A., Fink L.M., Kern P.A. The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes. Atherosclerosis. 158:(2):2001;297-301.
39. Bredie S.J., Tack C.J., Smits P., Stalenhoef A.F. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler. Thromb. Vasc. Biol. 17:(7):1997;1465-1471.
40. Godsland I.F., Rosankiewicz J.R., Proudler A.J., Johnston D.G. Plasma total homocysteine concentrations are unrelated to insulin sensitivity and components of the metabolic syndrome in healthy men. J. Clin. Endocrinol. Metab. 86:(2):2001;719-723.
41. Abbasi F., Facchini F., Humphreys M.H., Reaven G.M. Plasma homocysteine concentrations in healthy volunteers are not related to differences in insulin-mediated glucose disposal. Atherosclerosis. 146:(1):1999;175-178.
42. Giltay E.J., Hoogeveen E.K., Elbers J.M., Gooren L.J., Asscheman H., Stehouwer C.D. Insulin resistance is associated with elevated plasma total homocysteine levels in healthy, non-obese subjects. Atherosclerosis. 139:(1):1998;197-198.
43. Meigs J.B., Jacques P.F., Selhub J., Singer D.E., Nathan D.M., Rifai N., et al. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care. 24:(8):2001;1403-1410.